Skip to main content
Equibles
PTHS logo

PTHS · Pelthos Therapeutics Inc. · Earnings Call Transcripts & Audio

Track PTHS — free

Use PTHS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTHS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.01 +0.09 (+0.43%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — cleared May 14, 2026

The latest filing states the doubt was alleviated.

“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”
View the 10-Q filed May 14, 2026
Market Cap
$84.95M
Shares
3.83M
Volume · Sep 30 5453 Avg daily vol (3M) 58.25K

Pelthos Therapeutics Inc. Earnings Call Transcripts

Quarterly earnings calls for Pelthos Therapeutics Inc. (PTHS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $7.41M −$16.24M '25 Q3 25-11-13 · $9.39M −$21.66M '25 Q4 26-03-19 · $10.91M −$25.07M '26 Q1 26-05-14 LATEST · $15.60M −$23.42M '26 Q2 26-08-13
Annual General Meeting
Investor event
2026-09-29
Pelthos Therapeutics Inc. (PTHS) September 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Positive tone Future Product Launches Seasonality and Volatility Competitive Landscape
Revenue
$15.60M
Diluted EPS
$-6.62
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Confident tone Zelsudmi launch performance Zepi and Zeglize pipeline PBM contract and access
Revenue
$10.91M
Diluted EPS
$-7.57
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call
Revenue
$9.39M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript
Confident tone ZELSUVMI launch performance Xepi acquisition and portfolio Pricing and market access
Revenue
$7.41M
Diluted EPS
$-5.30
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–5 of 5 earnings calls
Key facts CIK 1919246 CUSIP 171126204 13F (30d) 2 filings 2 filers Visit website Investor relations